(Total Views: 609)
Posted On: 07/30/2023 10:25:45 AM
Post# of 154003
Interesting article re: Keytruda/ Pelareorep combo therapy for pancreatic Ca;
Of particular interest was the comment re: CCR5 upregulation as a "negative predictive biomarker for Pelareorep or other oncolytic therapy" , which seems to me to point at another possible indication for Leronlimab. Pancreatic Ca is such a dire disease that a triple combo of Keytruda/Leronlimab/Pelareorep seems like a reasonable option for further study once K/L has been looked at and found to be effective.
https://aacrjournals.org/clincancerres/articl...-Oncolytic
Also worth a look is the ONCY chart, gives us an idea of what a wild ride these fledgling biotechs can be.
Of particular interest was the comment re: CCR5 upregulation as a "negative predictive biomarker for Pelareorep or other oncolytic therapy" , which seems to me to point at another possible indication for Leronlimab. Pancreatic Ca is such a dire disease that a triple combo of Keytruda/Leronlimab/Pelareorep seems like a reasonable option for further study once K/L has been looked at and found to be effective.
https://aacrjournals.org/clincancerres/articl...-Oncolytic
Also worth a look is the ONCY chart, gives us an idea of what a wild ride these fledgling biotechs can be.
(1)
(0)
